Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Cardioprotection in CHD Patients Undergoing PCI
NCT03095469Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexmedetomidine in myocardial infarction type 4a and Myocardial injury, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: incidence of myocardial infarction type 4a at 48 hours. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
myocardial infarction type 4aMyocardial injury
Beyond the preview
Go deeper on NCT03095469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095469.